No Data
No Data
No Data
No Data
No Data
Borui Pharmaceutical (688166.SH): Net profit of 640.69,900 yuan in the first quarter decreased by 9.47% year-on-year
On April 27, Ge Longhui Pharmaceutical (688166.SH) released its report for the first quarter of 2024, achieving operating income of 340 million yuan, an increase of 11.54%; net profit attributable to shareholders of listed companies of 640.699 million yuan, a year-on-year decrease of 9.47%; net profit attributable to shareholders of listed companies after deducting non-recurring profits and losses of 64.214,400 yuan, a year-on-year decrease of 7.89%; and basic earnings per share of 0.15 yuan.
Gelonghui FinanceApr 26 22:53 ET
BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 5.8% Gain Last Week Benefited Both Retail Investors Who Own 34% as Well as Insiders
Key Insights Significant control over BrightGene Bio-Medical Technology by retail investors implies that the general public has more power to influence management and governance-related decisions 51
Simply Wall StApr 23 20:38 ET
Borui Pharmaceutical (688166.SH): Selamectin (veterinary) API obtained European CEP certificate
Glonghui, April 19 | Borui Pharmaceutical (688166.SH) announced that the active ingredient selamectin (veterinary) has received a CEP (European Pharmacopeia Suitability Certification) certificate issued by the European Medicines Quality Administration (“EDQM”). Xylamectin (veterinary use) is suitable for the treatment and prevention of parasitic infections in cats/dogs.
Gelonghui FinanceApr 19 05:08 ET
Borui Pharmaceutical (688166.SH): Completed repurchases, cumulative repurchases of 0.0860% of shares
Gelonghui, April 18 | Borui Pharmaceutical (688166.SH) announced that as of the disclosure date of this announcement, the company has completed this share repurchase. The company has repurchased 363,461 shares of the company through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.0860% of the company's total share capital. The highest price of the repurchase transaction was 29.94 yuan/share, the lowest price was 25.17 yuan/share, and the total amount of capital paid was RMB 10,005,126.10 (excluding transaction fees such as stamp duty and transaction commissions).
Gelonghui FinanceApr 18 06:57 ET
Borui Pharmaceutical (688166.SH): A total of 99,900 shares have been repurchased
Gelonghui, April 1 | Borui Pharmaceutical (688166.SH) announced that as of March 31, 2024, the company had repurchased 99,900 shares through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.0236% of the company's total share capital of 422,466,561 shares. The highest purchase price was 29.94 yuan/share, the lowest price was 28.87 yuan/share, and the total amount of capital paid was RMB 2,941,496.33 (excluding transaction fees such as stamp duty and transaction fees).
Gelonghui FinanceApr 1 08:30 ET
Borui Pharmaceutical (688166.SH): initial repurchase of 99,900 shares
Glonghui, March 27, 丨 Borui Pharmaceutical (688166.SH) announced that on March 27, 2024, the company repurchased 99,900 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.0236% of the company's total share capital of 422,466,561 shares. The highest price of the repurchase transaction was 29.94 yuan/share, the lowest price was 28.87 yuan/share, and the total amount of capital paid was RMB 2,941,496.33 (excluding transaction fees such as stamp duty and transaction fees).
Gelonghui FinanceMar 27 04:44 ET
No Data
No Data